Search
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
CY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
IDM-4
go.drugbank.com/drugs/DB05438ExperimentalTrials of this drug have most likely been discontinued by the manufacturer. … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.
P54
go.drugbank.com/drugs/DB05451ExperimentalIt inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. … P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis.
Isothipendyl
go.drugbank.com/drugs/DB08802InvestigationalIsothipendyl is an antihistamine and anticholinergic used as an antipruritic.
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Imisopasem manganese
go.drugbank.com/drugs/DB04976InvestigationalM40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Synonyms: 2-((2R)-1-((2E)-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)PROP-2-ENOYL)PIPERIDIN-2-YL)ACETIC ACID, 2-PIPERIDINEACETIC ACID, 1-((2E)-1-OXO-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-2-PROPEN-1-YL)-, (2R)-Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalIt is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.